{"id":1544898,"date":"2025-07-02T11:45:00","date_gmt":"2025-07-02T15:45:00","guid":{"rendered":"https:\/\/bugaluu.com\/news\/?p=1544898"},"modified":"2025-07-02T11:45:00","modified_gmt":"2025-07-02T15:45:00","slug":"centene-crashes-after-pulling-2025-guidance-on-unexpected-risk-adjustment-results","status":"publish","type":"post","link":"https:\/\/bugaluu.com\/news\/centene-crashes-after-pulling-2025-guidance-on-unexpected-risk-adjustment-results\/1544898\/","title":{"rendered":"Centene Crashes After Pulling 2025 Guidance On Unexpected Risk Adjustment Results"},"content":{"rendered":"<p><span class=\"field field--name-title field--type-string field--label-hidden\">Centene Crashes After Pulling 2025 Guidance On Unexpected Risk Adjustment Results<\/span><\/p>\n<div class=\"clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item\">\n<p>Centene shares crashed in premarket trading after the\u00a0health insurer\u00a0<strong>withdrew its 2025 guidance<\/strong> due to weaker-than-expected trends in the Affordable Care Act Marketplace and ongoing Medicaid cost pressures. The <strong>health insurer warned<\/strong> of a $1.8 billion earnings headwind, <strong>prompting downgrades from Wall Street<\/strong>.\u00a0<\/p>\n<p>Centene, one of the\u00a0largest health insurers in the U.S.,\u00a0<a href=\"https:\/\/investors.centene.com\/2025-07-01-CENTENE-CORPORATION-WITHDRAWS-2025-GUIDANCE\">disclosed<\/a> on Tuesday evening new data from\u00a0an independent actuarial firm,\u00a0Wakely, <strong>covering about 72% of its\u00a0ACA Marketplace membership<\/strong>, revealed significantly worse-than-expected results.<\/p>\n<p><strong>Wakely&#8217;s data reveals:<\/strong><\/p>\n<p><strong><em>Lower-than-expected market growth<\/em><\/strong><em> and<\/em><\/p>\n<p><em>Much <\/em><strong><em>higher aggregate morbidity<\/em><\/strong><em> than Centene had assumed for its risk adjustment revenue.<\/em><\/p>\n<p>As a result, Centene now preliminarily <strong>estimates a $1.8 billion reduction in its net risk adjustment revenue for 2025<\/strong>, translating into a $2.75 hit to adjusted diluted EPS.\u00a0According to FactSet data, Wall Street analysts\u00a0had expected full-year adjusted earnings of around $7.28 a share.\u00a0<\/p>\n<p>&#8220;The Company does not have information or estimates for its remaining seven Marketplace states, <strong>but anticipates, due to the morbidity trends observed in the 22 states, an additional reduction to its net risk adjustment revenue transfer expectation with a corresponding adjusted diluted EPS impact<\/strong>,&#8221;\u00a0Centene stated in a press release.<\/p>\n<p><strong>Another industry bellwether<\/strong>, UnitedHealth, recently <a href=\"https:\/\/www.zerohedge.com\/medical\/unitedhealth-group-shares-plunge-abrupt-ceo-exit-suspends-2025-outlook\">slashed<\/a> its full-year guidance and replaced its chief executive. Higher-than-expected medical costs have sparked broader concerns across the entire insurance sector.<\/p>\n<p>Analysts were full of gloom, with <strong>UBS cutting its rating on\u00a0Centene to\u00a0neutral<\/strong>, citing significantly weaker near-term earnings.<\/p>\n<p><a href=\"https:\/\/cms.zerohedge.com\/s3\/files\/inline-images\/Snag_2ffdc3d2.png?itok=EC_JSaOa\"><\/a><\/p>\n<p>Here are first takes from Wall Street (courtesy of Bloomberg):<\/p>\n<p><strong>UBS (neutral)<\/strong><\/p>\n<p><em>UBS cuts Centene to neutral from buy immediately following the withdrawn guidance; broker now sees 2025\/2026 EPS at $3.25, representing a 55% decline<\/em><\/p>\n<p><em>&#8220;With the unexpected risk adjustment results in Marketplace and persistent Medicaid cost trends, the company&#8217;s risk near term earnings has been significantly reduced&#8221;<\/em><\/p>\n<p><strong>JPMorgan (neutral) <\/strong><\/p>\n<p><em>Analyst John Stansel cuts to neutral from overweight following news; says new price target of $48 from \u20ac75 reflects estimated ACA headwinds as well as &#8220;incremental&#8221; Medicaid pressure, &#8220;assuming that CNC is able to reprice at least a portion of its book into 2026&#8221;<\/em><\/p>\n<p><em>Says any information on Centene&#8217;s approach to the ACA Marketplace in 2026 and recent regulatory changes will be key when company reports earnings on July 25<\/em><\/p>\n<p><strong>Barclays (equalweight)<\/strong><\/p>\n<p><em>Analyst Andrew Mok calls ACA update &#8220;materially negative;&#8221; says it comes after recently-received industry data that showed Centene&#8217;s cited membership growth was lower than expected, &#8220;likely driven by integrity rules&#8221; <\/em><\/p>\n<p><em>Adds that implied morbidity was &#8220;significantly higher&#8221; than Centene&#8217;s expectations, driving an earnings headwind of as much as $1.8 billion for 2025, representing a $2.75 EPS impact<\/em><\/p>\n<p><strong>Jefferies (hold) <\/strong><\/p>\n<p><em>Analyst David Windley says Centene&#8217;s move confirms Jefferies fears that the prior-year 2025 risk pool is &#8220;deteriorating and plans have mispriced the risk pool&#8221; with firms assuming healthy growth<\/em><\/p>\n<p><em>&#8220;Investors should remember that CNC&#8217;s risk adjustment is moving unfavorably because others&#8217; books are feeling claims pressure,&#8221; Windley flags<\/em><\/p>\n<p><strong>Centene shares plunged as much as 27%<\/strong> in premarket trading in New York, hitting levels last seen in 2017. As of Tuesday&#8217;s close, the stock was down roughly 6.5% year-to-date.<\/p>\n<p><a href=\"https:\/\/cms.zerohedge.com\/s3\/files\/inline-images\/Snag_2ffd5ac8.png?itok=yNH04ysB\"><\/a><\/p>\n<p>. . .<\/p>\n<\/div>\n<p>      <span class=\"field field--name-uid field--type-entity-reference field--label-hidden\"><a title=\"View user profile.\" href=\"https:\/\/cms.zerohedge.com\/users\/tyler-durden\" class=\"username\">Tyler Durden<\/a><\/span><br \/>\n<span class=\"field field--name-created field--type-created field--label-hidden\">Wed, 07\/02\/2025 &#8211; 07:45<\/span><\/p>\n<p>\u200b<a href=\"https:\/\/www.zerohedge.com\/markets\/centene-crashes-after-pulling-2025-guidance-unexpected-risk-adjustment-results\" target=\"_blank\" class=\"\">https:\/\/www.zerohedge.com\/markets\/centene-crashes-after-pulling-2025-guidance-unexpected-risk-adjustment-results<\/a>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Centene Crashes After Pulling 2025 Guidance On Unexpected Risk Adjustment Results Centene shares crashed in premarket trading after the\u00a0health insurer\u00a0withdrew its 2025 guidance due to&#8230;<\/p>\n","protected":false},"author":0,"featured_media":1544899,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1544898","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","wpcat-1-id"],"_links":{"self":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/posts\/1544898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/comments?post=1544898"}],"version-history":[{"count":0,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/posts\/1544898\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/media\/1544899"}],"wp:attachment":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/media?parent=1544898"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/categories?post=1544898"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/tags?post=1544898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}